Johnson & Johnson (JNJ) Shares Sold by Tukman Grossman Capital Management Inc.

Tukman Grossman Capital Management Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ) by 48.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 83,038 shares of the company’s stock after selling 79,000 shares during the period. Johnson & Johnson comprises 8.1% of Tukman Grossman Capital Management Inc.’s portfolio, making the stock its 3rd biggest holding. Tukman Grossman Capital Management Inc.’s holdings in Johnson & Johnson were worth $10,796,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares in the last quarter. IHT Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $124,000. Institutional investors and hedge funds own 65.70% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) opened at $141.78 on Wednesday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The firm has a market cap of $380,890.00, a P/E ratio of 19.95, a P/E/G ratio of 2.90 and a beta of 0.80. Johnson & Johnson has a fifty-two week low of $110.76 and a fifty-two week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the previous year, the business earned $1.68 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. research analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.37%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

Several research firms have recently weighed in on JNJ. Piper Jaffray Companies reaffirmed a “hold” rating and set a $120.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 4th. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective for the company. in a report on Monday, September 18th. Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. UBS reaffirmed a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a report on Thursday, August 31st. Finally, Wells Fargo & Company raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $140.00 to $149.00 in a report on Monday, October 9th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $145.04.

TRADEMARK VIOLATION WARNING: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/12/20/johnson-johnson-jnj-shares-sold-by-tukman-grossman-capital-management-inc.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply